{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"19.0","value":"3.7"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"41.0","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"30.8","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"Complete Remission"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"12.8","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"41.0","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"30.8","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"Partial Remission"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"12.8","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"41.0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"12.8","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"41.0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Stringent Compete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"the best response designation over the study as a whole, recorded between the date of first dose and the last efficacy assessment prior to subsequent therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"3mg/kg of nivolumab","id":"OG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"OG002","title":"Nivolumab + Lirilumab"}],"paramType":"NUMBER","populationDescription":"All Treated participants with available measurements in the Multiple Myeloma (MM) Group","reportingStatus":"POSTED","timeFrame":"Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to 5 months Nivo Liri: approximately up to 4 years 1 month","title":"Best Overall Response - Multiple Myeloma Group","type":"SECONDARY","unitOfMeasure":"Percentage"}